# Avenue Therapeutics Inc. (ATXI)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1M  
**Price:** $0.36

> Avenue Therapeutics is a specialty pharmaceutical company focused on developing and commercializing therapies for treating neurologic diseases. The company is headquartered in Bay Harbor Islands, Florida and operates as a subsidiary of Fortress Biotech. Avenue Therapeutics pursues a focused pipeline of product candidates designed to address serious neurological conditions. These include AJ201, currently in clinical development for spinal and bulbar muscular atrophy, intravenous tramadol for post-operative acute pain management as a potential alternative to conventional opioids in intensive care settings, and BAER-101 for epilepsy and panic disorders. The company's strategy centers on acquiring, licensing, and commercializing pharmaceutical products tailored for hospital intensive care environments. By focusing on underserved neurological and rare disease indications, Avenue Therapeutics aims to provide therapeutic options that address unmet medical needs in specialized treatment settings.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1M | — | -$3M | -$3M | — |
| 2024 | — | — | -$11M | -$12M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $3M | $1M | $2M | $3M | — |
| 2024 | $3M | $816,000 | $3M | $3M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$2M | — | — |
| 2024 | -$9M | — | — |
| 2023 | -$9M | — | — |
| 2022 | -$8M | — | — |
| 2021 | -$4M | — | — |
| 2020 | -$5M | — | — |
| 2019 | -$26M | — | — |
| 2018 | -$18M | — | — |
| 2017 | -$7M | — | — |
| 2016 | -$2M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/ATXI)